Citizens Jmp Begins Coverage on Sionna Therapeutics (NASDAQ:SION)

Analysts at Citizens Jmp assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION) in a note issued to investors on Tuesday. The brokerage set an “outperform” rating and a $63.00 price target on the stock. Citizens Jmp’s price target suggests a potential upside of 74.52% from the company’s current price.

A number of other research analysts have also commented on the company. Lifesci Capital started coverage on Sionna Therapeutics in a report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price target for the company. Royal Bank Of Canada reiterated an “underperform” rating and set a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. BTIG Research reissued a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.63.

Sionna Therapeutics Stock Performance

NASDAQ SION opened at $36.10 on Tuesday. The stock has a 50-day simple moving average of $40.23 and a 200 day simple moving average of $34.63. Sionna Therapeutics has a twelve month low of $7.26 and a twelve month high of $45.00. The stock has a market capitalization of $1.61 billion and a PE ratio of -7.41.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the sale, the director directly owned 3,530,702 shares of the company’s stock, valued at approximately $157,398,695.16. The trade was a 0.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the sale, the insider owned 6,494,962 shares in the company, valued at approximately $259,798,480. This represents a 3.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 385,568 shares of company stock valued at $16,040,975 over the last quarter. 3.90% of the stock is owned by company insiders.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently bought and sold shares of the stock. Viking Global Investors LP raised its stake in Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after acquiring an additional 242,427 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Sionna Therapeutics by 2.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after purchasing an additional 51,589 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after purchasing an additional 41,797 shares in the last quarter. Jennison Associates LLC increased its position in shares of Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after purchasing an additional 117,903 shares in the last quarter. Finally, Braidwell LP bought a new position in Sionna Therapeutics during the 2nd quarter valued at about $18,770,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.